| Name | Title | Contact Details |
|---|
The M+A name represents two powerful brands – Mountville and Andersen – with nearly a century of combined experience developing and manufacturing mats designed to make environments safer, cleaner, and more comfortable. In 1963, the late Emmett Hart, with his wife Nancy by his side, established Mountville Mills. A little over a decade later, in 1974, the late Walter Andersen established The Andersen Company. Throughout the years, the companies drove innovations in their respective markets; Mountville in the textile rental market, and Andersen in the janitorial/sanitary supply markets. Outstanding quality and customer service paved the way for future generations of Harts and Andersens to expand the business. In 1999, these flagship brands joined forces to become the largest mat manufacturer in the world, and in 2018 we made the union official with a name change to M+A Matting. For decades, weve been a symbol of quality and customer service. Were the driving force in the mat industry, developing the next generation of mats designed to provide superior safety, cleanliness, and comfort to workers and customers across the world. Our diverse product mix is a direct reflection of our diverse customers and end users who span virtually every industry – healthcare, hospitality, food service, retail, education, industrial, and commercial.
Geofabrica is a manufacturing technology development company specializing in customized additive manufacturing systems for factory and expeditionary applications. We build innovative solutions to unlock the economic and production potential of 3D printing and additive technologies for metal, plastic, and composite applications. We create application-specific devices and processes to help customers overcome the limitations of current technologies and help them achieve a competitive advantage within the evolving digital manufacturing landscape. ITAR registered, JCP certified, NIST 800-171 compliant.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.